Oral Plus Topical Administration of Enrofloxacin-Hydrochloride-Dihydrate for the Treatment of Unresponsive Canine Pyoderma. A Clinical Trial
An outpatient clinical trial on unresponsive deep-bacterial canine pyoderma (UDCP), without a control group, is presented. The chosen treatment was implemented with a new crystal-solvate of enrofloxacin (enrofloxacin HCl-2H<sub>2</sub>O or enro-C), in a dual scheme, i.e., 10 mg/kg/day PO...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-05-01
|
| Series: | Animals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-2615/10/6/943 |
| _version_ | 1827715897288032256 |
|---|---|
| author | Lilia Gutierrez Graciela Tapia Luis Ocampo Minerva Monroy-Barreto Hector Sumano |
| author_facet | Lilia Gutierrez Graciela Tapia Luis Ocampo Minerva Monroy-Barreto Hector Sumano |
| author_sort | Lilia Gutierrez |
| collection | DOAJ |
| description | An outpatient clinical trial on unresponsive deep-bacterial canine pyoderma (UDCP), without a control group, is presented. The chosen treatment was implemented with a new crystal-solvate of enrofloxacin (enrofloxacin HCl-2H<sub>2</sub>O or enro-C), in a dual scheme, i.e., 10 mg/kg/day PO, plus its topical administration, prepared as 0.5% in an alginate gel, thrice per day. Fifty-five cases that were unsuccessfully treated previously with another antibacterial drug, were selected and then classified as severe or very severe, according to a clinical score tailored for this trial. Aerobic bacteriological cultures of skin lesions and antibacterial sensitivity tests, were performed. Hematological status, liver, and kidney functions were determined before and after treatment. A complete success was obtained in 32 severe and 23 very severe, cases. The main bacterial isolates were: <i>Staphylococcus intermedius</i> (19/99), <i>Staphylococcus pseudintermedius</i> (16/99), <i>Staphylococcus epidermidis</i> (15/99), <i>Staphylococcus pyogenes</i> (14/99), <i>Staphylococcus saprophyticus</i>, <i>Streptococcus</i> sp., and others including <i>Pseudomonas aeruginosa</i> (6/99). The average duration of treatment was 8.03 days ± 2.1 SD and 12.0 ± 2.4 days, for dogs with severe or very severe UDCP, respectively. The adverse effects caused by enro-C were inconsequential and the hematological tests showed no deviations from normality. The use of enro-C administered dually to treat UDCP, is considered safe and highly effective. |
| first_indexed | 2024-03-10T19:30:15Z |
| format | Article |
| id | doaj.art-02aa064c402242a7893821d4301bc63a |
| institution | Directory Open Access Journal |
| issn | 2076-2615 |
| language | English |
| last_indexed | 2024-03-10T19:30:15Z |
| publishDate | 2020-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Animals |
| spelling | doaj.art-02aa064c402242a7893821d4301bc63a2023-11-20T02:10:02ZengMDPI AGAnimals2076-26152020-05-0110694310.3390/ani10060943Oral Plus Topical Administration of Enrofloxacin-Hydrochloride-Dihydrate for the Treatment of Unresponsive Canine Pyoderma. A Clinical TrialLilia Gutierrez0Graciela Tapia1Luis Ocampo2Minerva Monroy-Barreto3Hector Sumano4Departamento de Fisiología y Farmacologia, Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Autónoma de México, Avenida Universidad 3000, Coyoacan, Mexico City 04510, MexicoDepartamento de Genética y Bioestadística, Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Autónoma de México, Avenida Universidad 3000, Coyoacan, Mexico City 04510, MexicoDepartamento de Fisiología y Farmacologia, Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Autónoma de México, Avenida Universidad 3000, Coyoacan, Mexico City 04510, MexicoDepartamento de Química Analítica, Facultad de Química, Universidad Nacional Autónoma de México, Avenida Universidad 3000, Coyoacan, Mexico City 04510, MexicoDepartamento de Fisiología y Farmacologia, Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Autónoma de México, Avenida Universidad 3000, Coyoacan, Mexico City 04510, MexicoAn outpatient clinical trial on unresponsive deep-bacterial canine pyoderma (UDCP), without a control group, is presented. The chosen treatment was implemented with a new crystal-solvate of enrofloxacin (enrofloxacin HCl-2H<sub>2</sub>O or enro-C), in a dual scheme, i.e., 10 mg/kg/day PO, plus its topical administration, prepared as 0.5% in an alginate gel, thrice per day. Fifty-five cases that were unsuccessfully treated previously with another antibacterial drug, were selected and then classified as severe or very severe, according to a clinical score tailored for this trial. Aerobic bacteriological cultures of skin lesions and antibacterial sensitivity tests, were performed. Hematological status, liver, and kidney functions were determined before and after treatment. A complete success was obtained in 32 severe and 23 very severe, cases. The main bacterial isolates were: <i>Staphylococcus intermedius</i> (19/99), <i>Staphylococcus pseudintermedius</i> (16/99), <i>Staphylococcus epidermidis</i> (15/99), <i>Staphylococcus pyogenes</i> (14/99), <i>Staphylococcus saprophyticus</i>, <i>Streptococcus</i> sp., and others including <i>Pseudomonas aeruginosa</i> (6/99). The average duration of treatment was 8.03 days ± 2.1 SD and 12.0 ± 2.4 days, for dogs with severe or very severe UDCP, respectively. The adverse effects caused by enro-C were inconsequential and the hematological tests showed no deviations from normality. The use of enro-C administered dually to treat UDCP, is considered safe and highly effective.https://www.mdpi.com/2076-2615/10/6/943unresponsive canine deep-pyodermaenrofloxacin hydrochloride-dihydratetreatmentclinical trial |
| spellingShingle | Lilia Gutierrez Graciela Tapia Luis Ocampo Minerva Monroy-Barreto Hector Sumano Oral Plus Topical Administration of Enrofloxacin-Hydrochloride-Dihydrate for the Treatment of Unresponsive Canine Pyoderma. A Clinical Trial Animals unresponsive canine deep-pyoderma enrofloxacin hydrochloride-dihydrate treatment clinical trial |
| title | Oral Plus Topical Administration of Enrofloxacin-Hydrochloride-Dihydrate for the Treatment of Unresponsive Canine Pyoderma. A Clinical Trial |
| title_full | Oral Plus Topical Administration of Enrofloxacin-Hydrochloride-Dihydrate for the Treatment of Unresponsive Canine Pyoderma. A Clinical Trial |
| title_fullStr | Oral Plus Topical Administration of Enrofloxacin-Hydrochloride-Dihydrate for the Treatment of Unresponsive Canine Pyoderma. A Clinical Trial |
| title_full_unstemmed | Oral Plus Topical Administration of Enrofloxacin-Hydrochloride-Dihydrate for the Treatment of Unresponsive Canine Pyoderma. A Clinical Trial |
| title_short | Oral Plus Topical Administration of Enrofloxacin-Hydrochloride-Dihydrate for the Treatment of Unresponsive Canine Pyoderma. A Clinical Trial |
| title_sort | oral plus topical administration of enrofloxacin hydrochloride dihydrate for the treatment of unresponsive canine pyoderma a clinical trial |
| topic | unresponsive canine deep-pyoderma enrofloxacin hydrochloride-dihydrate treatment clinical trial |
| url | https://www.mdpi.com/2076-2615/10/6/943 |
| work_keys_str_mv | AT liliagutierrez oralplustopicaladministrationofenrofloxacinhydrochloridedihydrateforthetreatmentofunresponsivecaninepyodermaaclinicaltrial AT gracielatapia oralplustopicaladministrationofenrofloxacinhydrochloridedihydrateforthetreatmentofunresponsivecaninepyodermaaclinicaltrial AT luisocampo oralplustopicaladministrationofenrofloxacinhydrochloridedihydrateforthetreatmentofunresponsivecaninepyodermaaclinicaltrial AT minervamonroybarreto oralplustopicaladministrationofenrofloxacinhydrochloridedihydrateforthetreatmentofunresponsivecaninepyodermaaclinicaltrial AT hectorsumano oralplustopicaladministrationofenrofloxacinhydrochloridedihydrateforthetreatmentofunresponsivecaninepyodermaaclinicaltrial |